Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibody
Biotech
Gilead gives up on $4.9B antibody magrolimab
Gilead dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline.
Nick Paul Taylor
Apr 26, 2024 10:04am
J&J targets rare maternal-fetal disease: 'We're going for this'
Apr 2, 2024 11:23am
Pfizer axes phase 3 sickle cell study, cites recruitment issues
Mar 26, 2024 5:31pm
With new data in hand, Astria makes ph. 3 wish on shooting star
Mar 25, 2024 10:46am
CytoDyn finally clears FDA hold on HIV program after 2 years
Feb 29, 2024 10:20am
Connecting the dots: Asthma asset aces phase 2b trial
Dec 12, 2023 11:00am